On Monday, Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), subtract -4.79% and closed at $1.79 in the last trading session. The last trading range of the stock ranges between $1.74 and $1.93. Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, is reporting translational data supporting the mechanism of action of intratumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist from the ongoing Phase 1 dose escalating clinical trial. In this trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma with disease that is refractory to anti-PD-1 inhibitors, and have minimal options and low expectation of clinical response with ipilimumab treatment alone. Taken together, the formerly stated early clinical responses and the supporting mechanism of action translational data being presented recently, indicate that intratumoral IMO-2125 is a potent agent for the stimulation of the tumor microenvironment.
In the oral presentation at the 2016 Society for Immunotherapy of Cancer Annual Meeting (SITC), entitled “Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanoma,” Cara Haymaker, Ph.D., from the University of Texas, MD Anderson Cancer Center, presented an overview of the modulation of the tumor microenvironment through the unique mechanism of action of intratumoral IMO-2125 and offered an update on the initial findings of the translational data through the first cohorts of the trial. Immunological analysis of the biopsy taken from the lesion injected with IMO-2125 showed rapid dendritic cell maturation which is a critical first step in the induction of the immune cascade within the tumor microenvironment. During the treatment period, T-cell expansion and activation and importantly, immune infiltration was observed in the biopsied distant lesions of the responding patients, demonstrating the abscopal effect.
GameStop Corp. (NYSE:GME), jumped 3.00% and closed at $22.99 in the last trading session. The last trading range of the stock ranges between $22.40 and $23.29. The company’s Market capitalization is $2.44 Billion with the total Outstanding Shares of 103.98 million. With less than a week left before the 2016 presidential election, many voters are still undecided while polls show the candidates running neck and neck. In October, GameStop, a family of specialty retail brands that makes the most popular technologies affordable and simple, conducted a presidential poll of its own; one of its PowerUp Rewards™ members, with “fun” as the main platform, to find out how video game characters would fare if they were running for president and vice president of the United States.
GameStop surveyed more than 500 men and women ages 18-44. The survey revealed those voting would elect Mario and Luigi as president and vice president, in addition to other fun information about video games and our current candidates. GameStop wasn’t surprised that Mario and Luigi won the election as they are famous for their ‘bro-based moves’ that assist them remove major obstacles, jump wide gaps and crush any bricks that get in the way.